Blood Bactericidal Activity
Serum Bactericidal Test
Microbial Sensitivity Tests
Colony Count, Microbial
Staphylococcus aureus
Anti-Infective Agents
Microbial Viability
Phagocytosis
Vancomycin
Ofloxacin
Cephalosporins
Escherichia coli
Neisseria meningitidis
Complement System Proteins
Pseudomonas aeruginosa
Bacteria
Rifampin
Gentamicins
alpha-Defensins
Neutrophils
Meningococcal Vaccines
Enterococcus faecalis
Antimicrobial Cationic Peptides
Diarylquinolines
Amikacin
Neisseria meningitidis, Serogroup B
Oxazolidinones
Penicillins
Gram-Negative Bacteria
Streptococcus pneumoniae
Quinolones
Acetamides
Staphylococcus
Ampicillin
Ceftizoxime
Antitubercular Agents
Bacteriolysis
Cefoperazone
Haemophilus influenzae
Cefonicid
Teicoplanin
Ceftazidime
Antibiotics, Antitubercular
Virginiamycin
Muramidase
Kanamycin
Serratia marcescens
Methicillin Resistance
Ceftriaxone
Isoniazid
Capnocytophaga
Pefloxacin
Drug Therapy, Combination
Streptococcus
Mycobacterium tuberculosis
Bacteroides fragilis
Drug Resistance, Bacterial
Bacteriocins
Opsonin Proteins
Cefamandole
Staphylococcus epidermidis
Drug Resistance, Microbial
Endocarditis, Bacterial
Lactoferrin
Erythromycin
Serum
Serum Bactericidal Antibody Assay
Cefixime
Rabbits
Amoxicillin-Potassium Clavulanate Combination
Klebsiella pneumoniae
Bacterial Outer Membrane Proteins
Aminoglycosides
Cefuroxime
4-Quinolones
Culture Media
Lipopolysaccharides
Vancomycin Resistance
Penicillin G
Phagocyte Bactericidal Dysfunction
Complement Activation
Enterobacteriaceae
Half-Life
Bacterial Vaccines
Thienamycins
Anti-Infective Agents, Local
Meningitis, Pneumococcal
Immune Sera
Piperacillin
Rifamycins
Salmonella typhimurium
Disinfectants
Moraxella (Branhamella) catarrhalis
Paneth Cells
Listeria monocytogenes
Enterococcus faecium
Meningitis, Meningococcal
Glycopeptides
Amoxicillin
Tobramycin
Gram-Positive Bacterial Infections
Area Under Curve
Imipenem
Blood Proteins
Neisseria meningitidis, Serogroup C
Minocycline
Sulbactam
Vaccines, Conjugate
Miocamycin
Dose-Response Relationship, Drug
Nitroblue Tetrazolium
Immunity
Luminescent Measurements
Polymyxin B
Electrolysis
Macrophages
Streptomycin
Neisseria meningitidis, Serogroup A
Drug Resistance, Multiple, Bacterial
Clarithromycin
Bacterial Capsules
Immunoglobulin G
Lactams
Norfloxacin
Moxalactam
Erythromycin Estolate
Metronidazole
Cephalexin
Erythromycin Ethylsuccinate
beta-Lactams
Methicillin-Resistant Staphylococcus aureus
Complement Pathway, Alternative
Penicillanic Acid
Drug Combinations
Enterobacter cloacae
Aztreonam
Proteus mirabilis
Amino Acid Sequence
Zeolites
Biofilms
Group II Phospholipases A2
Ornidazole
Enterococcus
Dibekacin
Molecular Sequence Data
Colistin
Hemolysis
Cathepsin G
Proteus vulgaris
Enterobacter
Hydrogen Peroxide
Cell Membrane Permeability
Polyanetholesulfonate
Ketolides
Complement Pathway, Classical
Neisseria gonorrhoeae
Defensins
beta-Lactamases
Salmonella
Leprostatic Agents
Silver
Lactoperoxidase
Klebsiella
Ampicillin Resistance
Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. (1/1592)
Antibodies against the class 4 outer membrane protein (OMP) from Neisseria meningitidis have been purified from sera from vaccinees immunized with the Norwegian meningococcal group B outer membrane vesicle vaccine. The human sera and purified antibodies reacted strongly with the class 4 OMP in immunoblots, whereas experiments with whole bacteria showed only weak reactions, indicating that the antibodies mainly reacted with parts of the class 4 molecule that were not exposed. The purified human anti-class 4 OMP antibodies and the monoclonal antibodies (MAbs) were neither bactericidal nor opsonic against live meningococci. Three new MAbs against the class 4 OMP were generated and compared with other, previously described MAbs. Three linear epitopes in different regions of the class 4 OMP were identified by the reaction of MAbs with synthetic peptides. The MAbs showed no blocking effect on bactericidal activity of MAbs against other OMPs. However, one of the eight purified human anti-class 4 OMP antibody preparations, selected from immunoblot reactions among sera from 27 vaccinees, inhibited at high concentrations the bactericidal effect of a MAb against the class 1 OMP. However, these antibodies were not vaccine induced, as they were present also before vaccination. Therefore, this study gave no evidence that vaccination with a meningococcal outer membrane vesicle vaccine containing the class 4 OMP induces blocking antibodies. Our data indicated that the structure of class 4 OMP does not correspond to standard beta-barrel structures of integral OMPs and that no substantial portion of the OmpA-like C-terminal region of this protein is located at the surface of the outer membrane. (+info)Role of the extracellular signal-regulated protein kinase cascade in human neutrophil killing of Staphylococcus aureus and Candida albicans and in migration. (2/1592)
Killing of Staphylococcus aureus and Candida albicans by neutrophils involves adherence of the microorganisms, phagocytosis, and a collaborative action of oxygen reactive species and components of the granules. While a number of intracellular signalling pathways have been proposed to regulate neutrophil responses, the extent to which each pathway contributes to the killing of S. aureus and C. albicans has not been clearly defined. We have therefore examined the effect of blocking one such pathway, the extracellular signal-regulated protein kinase (ERK) cascade, using the specific inhibitor of the mitogen-activated protein kinase/ERK kinase, PD98059, on the ability of human neutrophils to kill S. aureus and C. albicans. Our data demonstrate the presence of ERK2 and a 43-kDa form of ERK but not ERK1 in human neutrophils. Upon stimulation with formyl methionyl leucyl phenylalanine (fMLP), the activities of both ERK2 and the 43-kDa form were stimulated. Despite abrogating the activity of both ERK forms, PD98059 only slightly reduced the ability of neutrophils to kill S. aureus or C. albicans. This is consistent with our finding that PD98059 had no effect on neutrophil adherence or degranulation, although pretreatment of neutrophils with PD98059 inhibited fMLP-stimulated superoxide production by 50%, suggesting that a change in superoxide production per se is not strictly correlated with microbicidal activity. However, fMLP-stimulated chemokinesis was markedly inhibited, while random migration and fMLP-stimulated chemotaxis were partially inhibited, by PD98059. These data demonstrate, for the first time, that the ERK cascade plays only a minor role in the microbicidal activity of neutrophils and that the ERK cascade is involved primarily in regulating neutrophil migration in response to fMLP. (+info)The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children. (3/1592)
The UspA1 and UspA2 proteins from Moraxella catarrhalis share antigenic epitopes and are promising vaccine candidates. In this study, the levels and bactericidal activities of antibodies in sera from healthy adults and children toward UspA1 and UspA2 from the O35E strain were measured. Human sera contained antibodies to both proteins, and the levels of immunoglobulin G (IgG) antibodies were age dependent. Adult sera had significantly higher titers of IgG than child sera (P < 0.01). The IgG3 titers to the UspA proteins were higher than the IgG1 titers in the adults' sera, while the IgG1 titers were higher than the IgG3 titers in the children's sera (P < 0.05). The IgG antibodies in the sera from 2-month-old children appeared to be maternally derived, since the mean titer was significantly higher than that in sera from 6- to 7-month-old children (P < 0.05). Serum IgA antibodies to both UspA1 and UspA2 were low during the first 7 months of age but thereafter gradually increased along with the IgG titers. Analysis of sera absorbed with UspA1 or UspA2 showed that the antibodies to UspA1 and UspA2 were cross-reactive with each other and associated with serum bactericidal activity. Examination of affinity-purified human antibodies confirmed that naturally acquired antibodies to UspA1 and UspA2 were bactericidal and cross-reactive. These results support using UspA1 and UspA2 in a vaccine to prevent M. catarrhalis infections. (+info)Characterization of human bactericidal antibodies to Bordetella pertussis. (4/1592)
The Bordetella pertussis BrkA protein protects against the bactericidal activity of complement and antibody; however, some individuals mount an immune response that overcomes this bacterial defense. To further characterize this process, the bactericidal activities of sera from 13 adults with different modes of exposure to B. pertussis (infected as adults, occupational exposure, immunized with an acellular vaccine, or no identified exposure) against a wild-type strain and a BrkA complement-sensitive mutant were evaluated. All of the sera killed the BrkA mutant, suggesting past exposure to B. pertussis or cross-reactive organisms. Several samples had no or minimal activity against the wild type. All of the sera collected from the infected and occupationally exposed individuals but not all of the sera from vaccinated individuals had bactericidal activity against the wild-type strain, suggesting that some types of exposure can induce an immune response that can overcome the BrkA resistance mechanism. Adsorbing serum with the wild-type strain removed the bactericidal antibodies; however, adsorbing the serum with a lipopolysaccharide (LPS) mutant or an avirulent (bvg mutant) strain did not always result in loss of bactericidal activity, suggesting that antibodies to either LPS or bvg-regulated proteins could be bactericidal. All the samples, including those that lacked bactericidal activity, contained antibodies that recognized the LPS of B. pertussis. Bactericidal activity correlated best with the presence of the immunoglobulin G3 (IgG3) antibodies to LPS, the IgG subtype that is most effective at fixing complement. (+info)Isolation of Vibrio vulnificus serovar E from aquatic habitats in Taiwan. (5/1592)
The existence of strains of Vibrio vulnificus serovar E that are avirulent for eels is reported in this work. These isolates were recovered from water and oysters and differed from eel virulent strains in (i) fermentation and utilization of mannitol, (ii) ribotyping after HindIII digestion, and (iii) susceptibility to eel serum. Lipopolysaccharide of these strains lacked the highest molecular weight immunoreactive bands, which are probably involved in serum resistance. (+info)Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection. (6/1592)
Effective immunization against infection with Pseudomonas aeruginosa is difficult to evaluate because agglutinin levels decline rapidly. Because fractionation of hyperimmune sera often yields more specific antibody than can be accounted for by direct agglutination tests, an immunoglobulin-specific assay based on antiglobulin augmentation was used to characterize antibody responses of C3H/HeJ mice vaccinated with P. aeruginosa type 2 lipopolysaccharide. Nonagglutinating antibodies, initially detected at 2 weeks post-primary vaccination, were predominantly immunoglobulin G after 5 weeks, and they remained elevated at levels usually 32-fold higher than the direct titer throughout the 4-month study period. The sequential production of immunoglobulin M, then immunoglobulin G, followed that found in orthodox immunological responses. Sera that contained nonagglutinating antibodies but not direct agglutinins (14 to 16 weeks) enhanced phagocytosis of P. aeruginosa type 2 by macrophages from unimmunized mice and passively immunized mice against lethal challenge doses; bactericidal activity of these sera was not demonstrated in the presence or absence of complement. When challenged with 1, 10, and 100 50% lethal doses at 16 weeks, survival rates of actively immunized mice were significantly higher than those of unvaccinated mice (P < 0.001). Thus, at a time when no direct agglutinins were detectable, the augmented system detected nonagglutinating antibodies that could confer protracted resistance in vaccinated mice to pseudomonas infection. (+info)Effects of iron and culture filtrates on killing of Neisseria gonorrhoeae by normal human serum. (7/1592)
Neisseria gonorrhoeae GC9, both colony types T2 and T4, were killed by normal human serum, although populations of colony type T4 were more susceptible. Ferric ammonium citrate prevented the killing of populations of both T2 and T4 colony types. Other iron compounds tested showed no protective effect, nor did ammonium citrate or the divalent cations magnesium or calcium. A filtrate from cultures of an N. gonorrhoeae strain grown in a liquid defined medium showed a similar protective effect in the serum assay. The filtrate appeared to chelate iron, as measured by decreased ability of iron-free transferin to bind iron in the presence of the filtrate. However, the two effects did not appear to be related. Neither ferric ammonium citrate nor the culture filtrate sufficiently inactivated complement to account for protection. (+info)Type-specific opsonophagocytosis of group A Streptococcus by use of a rapid chemiluminescence assay. (8/1592)
A whole-blood chemiluminescence (CL) assay was developed to determine the presence of type-specific opsonic antibodies against group A streptococcus (GAS). Convalescent sera with high bactericidal activities against an M-1 serotype were used to opsonize different M-types of GAS. CL responses were monitored for 20 min, and results were expressed as integral counts/minute per phagocyte. CL responses of phagocytes incubated with M-1 GAS opsonized with homologous (M-1) serum were significantly higher than responses of phagocytes incubated with heterologous (M-3) GAS. Adsorption of convalescent serum against the homologous, but not the heterologous, strain markedly reduced the CL response, demonstrating type specificity. The CL assay showed a high correlation with the indirect bactericidal test (r=0.90). In conclusion, this CL assay is a rapid, highly sensitive, specific, and reproducible method for quantifying type-specific opsonic antibodies against GAS and will be a useful tool for future clinical, basic science, and epidemiological studies. (+info)The most common form of this disease is Meningococcal Group B (MenB). Symptoms often develop within hours or days after exposure, but can be nonspecific, such as fever, headache, and muscle aches.
Early signs that are more specific and suggestive of the diagnosis include neck stiffness, confusion, seizures, and rash. Diagnosis is by culture or PCR of a sterile site. Treatment consists of antibiotics that cover Neisseria meningitidis, which should be initiated promptly after recognition of the signs and symptoms.
Prevention with vaccines is recommended for infants at 2 months of age; boosters are given at 4 months, 6 months, and 12 to 15 months of age.
Staphylococcal infections can be classified into two categories:
1. Methicillin-Resistant Staphylococcus Aureus (MRSA) - This type of infection is resistant to many antibiotics and can cause severe skin infections, pneumonia, bloodstream infections and surgical site infections.
2. Methicillin-Sensitive Staphylococcus Aureus (MSSA) - This type of infection is not resistant to antibiotics and can cause milder skin infections, respiratory tract infections, sinusitis and food poisoning.
Staphylococcal infections are caused by the Staphylococcus bacteria which can enter the body through various means such as:
1. Skin cuts or open wounds
2. Respiratory tract infections
3. Contaminated food and water
4. Healthcare-associated infections
5. Surgical site infections
Symptoms of Staphylococcal infections may vary depending on the type of infection and severity, but they can include:
1. Skin redness and swelling
2. Increased pain or tenderness
3. Warmth or redness in the affected area
4. Pus or discharge
5. Fever and chills
6. Swollen lymph nodes
7. Shortness of breath
Diagnosis of Staphylococcal infections is based on physical examination, medical history, laboratory tests such as blood cultures, and imaging studies such as X-rays or CT scans.
Treatment of Staphylococcal infections depends on the type of infection and severity, but may include:
1. Antibiotics to fight the infection
2. Drainage of abscesses or pus collection
3. Wound care and debridement
4. Supportive care such as intravenous fluids, oxygen therapy, and pain management
5. Surgical intervention in severe cases.
Preventive measures for Staphylococcal infections include:
1. Good hand hygiene practices
2. Proper cleaning and disinfection of surfaces and equipment
3. Avoiding close contact with people who have Staphylococcal infections
4. Covering wounds and open sores
5. Proper sterilization and disinfection of medical equipment.
It is important to note that MRSA (methicillin-resistant Staphylococcus aureus) is a type of Staphylococcal infection that is resistant to many antibiotics, and can be difficult to treat. Therefore, early diagnosis and aggressive treatment are crucial to prevent complications and improve outcomes.
Causes and risk factors:
The most common cause of bacterial endocarditis is a bacterial infection that enters the bloodstream and travels to the heart. This can occur through various means, such as:
* Injecting drugs or engaging in other risky behaviors that allow bacteria to enter the body
* Having a weakened immune system due to illness or medication
* Having a previous history of endocarditis or other heart conditions
* Being over the age of 60, as older adults are at higher risk for developing endocarditis
Symptoms:
The symptoms of bacterial endocarditis can vary depending on the severity of the infection and the location of the infected area. Some common symptoms include:
* Fever
* Chills
* Joint pain or swelling
* Fatigue
* Shortness of breath
* Heart murmurs or abnormal heart sounds
Diagnosis:
Bacterial endocarditis is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:
* Blood cultures to identify the presence of bacteria in the bloodstream
* Echocardiogram to visualize the heart and detect any abnormalities
* Chest X-ray to look for signs of infection or inflammation in the lungs or heart
* Electrocardiogram (ECG) to measure the electrical activity of the heart
Treatment:
The treatment of bacterial endocarditis typically involves a combination of antibiotics and surgery. Antibiotics are used to kill the bacteria and reduce inflammation, while surgery may be necessary to repair or replace damaged heart tissue. In some cases, the infected heart tissue may need to be removed.
Prevention:
Preventing bacterial endocarditis involves good oral hygiene, regular dental check-ups, and avoiding certain high-risk activities such as unprotected sex or sharing of needles. People with existing heart conditions should also take antibiotics before dental or medical procedures to reduce the risk of infection.
Prognosis:
The prognosis for bacterial endocarditis is generally good if treatment is prompt and effective. However, delays in diagnosis and treatment can lead to serious complications such as heart failure, stroke, or death. Patients with pre-existing heart conditions are at higher risk for complications.
Incidence:
Bacterial endocarditis is a relatively rare condition, affecting approximately 2-5 cases per million people per year in the United States. However, people with certain risk factors such as heart conditions or prosthetic heart valves are at higher risk for developing the infection.
Complications:
Bacterial endocarditis can lead to a number of complications, including:
* Heart failure
* Stroke or brain abscess
* Kidney damage or failure
* Pregnancy complications
* Nerve damage or peripheral neuropathy
* Skin or soft tissue infections
* Bone or joint infections
* Septicemia (blood poisoning)
Prevention:
Preventive measures for bacterial endocarditis include:
* Good oral hygiene and regular dental check-ups to reduce the risk of dental infections
* Avoiding high-risk activities such as unprotected sex or sharing of needles
* Antibiotics before dental or medical procedures for patients with existing heart conditions
* Proper sterilization and disinfection of medical equipment
* Use of antimicrobial prophylaxis (prevention) in high-risk patients.
Emerging Trends:
Newly emerging trends in the management of bacterial endocarditis include:
* The use of novel antibiotics and combination therapy to improve treatment outcomes
* The development of new diagnostic tests to help identify the cause of infection more quickly and accurately
* The increased use of preventive measures such as antibiotic prophylaxis in high-risk patients.
Future Directions:
Future directions for research on bacterial endocarditis may include:
* Investigating the use of novel diagnostic techniques, such as genomics and proteomics, to improve the accuracy of diagnosis
* Developing new antibiotics and combination therapies to improve treatment outcomes
* Exploring alternative preventive measures such as probiotics and immunotherapy.
In conclusion, bacterial endocarditis is a serious infection that can have severe consequences if left untreated. Early diagnosis and appropriate treatment are crucial to improving patient outcomes. Preventive measures such as good oral hygiene and antibiotic prophylaxis can help reduce the risk of developing this condition. Ongoing research is focused on improving diagnostic techniques, developing new treatments, and exploring alternative preventive measures.
Phagocyte bactericidal dysfunction can be caused by a variety of factors, including genetic mutations, exposure to toxins, or infections with certain viruses or other pathogens that interfere with phagocyte function.
The consequences of phagocyte bactericidal dysfunction can include increased susceptibility to infections and the development of persistent or chronic infections, which can lead to a range of health problems and diseases.
Phagocyte bactericidal dysfunction is an important area of research in immunology and infectious disease, as understanding the mechanisms that control phagocyte function can help us develop new therapies and treatments for infections and other immune-related disorders.
Definition: Meningitis, pneumococcal, is an inflammatory disease caused by Streptococcus pneumoniae (pneumococcus) that affects the protective membranes (meninges) covering the brain and spinal cord, leading to a range of symptoms including fever, headache, vomiting, and altered mental status. It can be a severe and potentially life-threatening infection, particularly in certain patient populations such as children under 5 years old, older adults, and those with underlying medical conditions.
Epidemiology: Pneumococcal meningitis is relatively uncommon, but it remains an important public health concern, particularly in developed countries. According to the Centers for Disease Control and Prevention (CDC), there are approximately 350 cases of pneumococcal meningitis reported each year in the United States, resulting in about 10% of all cases of bacterial meningitis.
Risk Factors: Several risk factors have been identified for developing pneumococcal meningitis, including:
1. Age: Children under 5 years old and older adults are at increased risk.
2. Underlying medical conditions: Patients with conditions such as sickle cell disease, HIV/AIDS, and chronic lung disease are more likely to develop pneumococcal meningitis.
3. Weakened immune system: Those with compromised immune systems, such as those taking immunosuppressive medications or who have undergone organ transplants, are at higher risk.
4. Recent exposure to someone with pneumococcal disease: Close contact with someone who has recently been diagnosed with pneumococcal disease can increase the risk of developing the infection.
Clinical Presentation: Symptoms of pneumococcal meningitis can vary depending on the age of the patient, but common presentations include:
1. Fever
2. Headache
3. Vomiting
4. Altered mental status (in infants and young children) or confusion (in older adults)
5. Stiff neck
6. Sensitivity to light (photophobia)
7. Bulging of the soft spots on the skull in infants (in infants)
Diagnosis: The diagnosis of pneumococcal meningitis is based on a combination of clinical findings, laboratory tests, and imaging studies. Laboratory tests may include blood cultures, cerebrospinal fluid (CSF) cultures, and polymerase chain reaction (PCR) to detect the presence of S. pneumoniae. Imaging studies, such as CT or MRI scans, may be used to evaluate the brain and identify any signs of inflammation or abscesses.
Treatment: Pneumococcal meningitis is typically treated with antibiotics, which are usually given intravenously. The choice of antibiotic depends on the severity of the infection and the patient's age and medical history. In addition to antibiotics, supportive care may be provided to manage symptoms such as fever, headache, and muscle aches. In severe cases, hospitalization may be necessary to monitor and treat the infection.
Complications: Pneumococcal meningitis can lead to serious complications, including:
1. Hearing loss
2. Learning disabilities
3. Behavioral changes
4. Seizures
5. Brain damage
6. Death
Prevention: Pneumococcal conjugate vaccine (PCV) is recommended for children under the age of 2 years and for certain high-risk groups, such as adults over the age of 65 and people with certain medical conditions. The vaccine can help prevent pneumococcal meningitis and other serious infections caused by S. pneumoniae. Good hygiene practices, such as frequent handwashing, can also help prevent the spread of the bacteria.
Prognosis: With prompt and appropriate treatment, the prognosis for pneumococcal meningitis is generally good. However, in severe cases or those with complications, the prognosis may be poorer. In some cases, long-term sequelae such as hearing loss, learning disabilities, and behavioral changes may occur.
Incubation period: The incubation period for pneumococcal meningitis is typically between 2 and 4 days, but it can range from 1 to 10 days.
Diagnosis: Pneumococcal meningitis is diagnosed based on a combination of clinical symptoms, physical examination findings, laboratory tests, and imaging studies such as CT or MRI scans. Laboratory tests may include blood cultures, cerebrospinal fluid (CSF) analysis, and PCR testing to identify the presence of S. pneumoniae.
Treatment: Treatment for pneumococcal meningitis typically involves antibiotics and supportive care to manage symptoms such as fever, headache, and muscle aches. In severe cases, hospitalization may be necessary to monitor and treat the infection.
In conclusion, pneumococcal meningitis is a serious infection that can cause significant morbidity and mortality. Prompt diagnosis and appropriate treatment are essential to prevent long-term sequelae and improve outcomes for affected individuals.
Symptoms of meningococcal meningitis typically develop within 3-7 days after exposure and may include fever, headache, stiff neck, confusion, nausea and vomiting, sensitivity to light, and seizures. In severe cases, the infection can lead to shock, organ failure, and death within hours of the onset of symptoms.
Diagnosis is typically made by a combination of physical examination, laboratory tests (such as blood cultures and PCR), and imaging studies (such as CT or MRI scans). Treatment typically involves antibiotics, intravenous fluids, and supportive care to manage fever, pain, and other symptoms. In severe cases, hospitalization in an intensive care unit may be necessary.
Prevention of meningococcal meningitis includes the use of vaccines, good hygiene practices (such as frequent handwashing), and avoidance of close contact with people who are sick. A vaccine is available for children and teens, and some colleges and universities require students to be vaccinated before moving into dorms.
Early diagnosis and treatment are crucial in preventing long-term complications and reducing the risk of death from meningococcal meningitis. If you suspect that you or someone else may have meningococcal meningitis, it is important to seek medical attention immediately.
Blisters are caused by friction or rubbing against a surface, which causes the top layer of skin to separate from the underlying layer. This separation creates a space that fills with fluid, forming a blister. Blisters can also be caused by burns, chemical exposure, or other types of injury.
There are different types of blisters, including:
1. Friction blisters: These are the most common type of blister and are caused by friction or rubbing against a surface. They are often seen on the hands, feet, and buttocks.
2. Burn blisters: These are caused by burns and can be more severe than friction blisters.
3. Chemical blisters: These are caused by exposure to chemicals and can be very painful.
4. Blisters caused by medical conditions: Certain medical conditions, such as epidermolysis bullosa (a genetic disorder that affects the skin), can cause blisters to form easily.
Blisters can be treated in several ways, depending on their size and location. Small blisters may not require treatment and can heal on their own within a few days. Larger blisters may need to be drained and covered with a bandage to prevent infection. In severe cases, surgical intervention may be necessary.
Preventing blisters is key to avoiding the discomfort and pain they can cause. To prevent blisters, it is important to:
1. Wear properly fitting shoes and clothing to reduce friction.
2. Use lubricating creams or powders to reduce friction.
3. Take regular breaks to rest and allow the skin to recover.
4. Avoid using harsh chemicals or detergents that can cause irritation.
5. Keep the affected area clean and dry to prevent infection.
In conclusion, blisters are a common and uncomfortable condition that can be caused by a variety of factors. While they can be treated and managed, prevention is key to avoiding the discomfort and pain they can cause. By taking steps to prevent blisters and seeking medical attention if they do occur, individuals can reduce their risk of developing this uncomfortable condition.
Some common examples of gram-positive bacterial infections include:
1. Staphylococcus aureus (MRSA) infections: These are infections caused by methicillin-resistant Staphylococcus aureus, which is a type of gram-positive bacteria that is resistant to many antibiotics.
2. Streptococcal infections: These are infections caused by streptococcus bacteria, such as strep throat and cellulitis.
3. Pneumococcal infections: These are infections caused by pneumococcus bacteria, such as pneumonia.
4. Enterococcal infections: These are infections caused by enterococcus bacteria, such as urinary tract infections and endocarditis.
5. Candidiasis: This is a type of fungal infection caused by candida, which is a type of gram-positive fungus.
Gram-positive bacterial infections can be treated with antibiotics, such as penicillin and ampicillin, but the increasing prevalence of antibiotic resistance has made the treatment of these infections more challenging. In some cases, gram-positive bacterial infections may require more aggressive treatment, such as combination therapy with multiple antibiotics or the use of antifungal medications.
Overall, gram-positive bacterial infections can be serious and potentially life-threatening, so it is important to seek medical attention if symptoms persist or worsen over time.
Some common examples of bacterial infections include:
1. Urinary tract infections (UTIs)
2. Respiratory infections such as pneumonia and bronchitis
3. Skin infections such as cellulitis and abscesses
4. Bone and joint infections such as osteomyelitis
5. Infected wounds or burns
6. Sexually transmitted infections (STIs) such as chlamydia and gonorrhea
7. Food poisoning caused by bacteria such as salmonella and E. coli.
In severe cases, bacterial infections can lead to life-threatening complications such as sepsis or blood poisoning. It is important to seek medical attention if symptoms persist or worsen over time. Proper diagnosis and treatment can help prevent these complications and ensure a full recovery.
Here are some common types of E. coli infections:
1. Urinary tract infections (UTIs): E. coli is a leading cause of UTIs, which occur when bacteria enter the urinary tract and cause inflammation. Symptoms include frequent urination, burning during urination, and cloudy or strong-smelling urine.
2. Diarrheal infections: E. coli can cause diarrhea, abdominal cramps, and fever if consumed through contaminated food or water. In severe cases, this type of infection can lead to dehydration and even death, particularly in young children and the elderly.
3. Septicemia (bloodstream infections): If E. coli bacteria enter the bloodstream, they can cause septicemia, a life-threatening condition that requires immediate medical attention. Symptoms include fever, chills, rapid heart rate, and low blood pressure.
4. Meningitis: In rare cases, E. coli infections can spread to the meninges, the protective membranes covering the brain and spinal cord, causing meningitis. This is a serious condition that requires prompt treatment with antibiotics and supportive care.
5. Hemolytic-uremic syndrome (HUS): E. coli infections can sometimes cause HUS, a condition where the bacteria destroy red blood cells, leading to anemia, kidney failure, and other complications. HUS is most common in young children and can be fatal if not treated promptly.
Preventing E. coli infections primarily involves practicing good hygiene, such as washing hands regularly, especially after using the bathroom or before handling food. It's also essential to cook meat thoroughly, especially ground beef, to avoid cross-contamination with other foods. Avoiding unpasteurized dairy products and drinking contaminated water can also help prevent E. coli infections.
If you suspect an E. coli infection, seek medical attention immediately. Your healthcare provider may perform a urine test or a stool culture to confirm the diagnosis and determine the appropriate treatment. In mild cases, symptoms may resolve on their own within a few days, but antibiotics may be necessary for more severe infections. It's essential to stay hydrated and follow your healthcare provider's recommendations to ensure a full recovery.
Pulmonary tuberculosis typically affects the lungs but can also spread to other parts of the body, such as the brain, kidneys, or spine. The symptoms of pulmonary TB include coughing for more than three weeks, chest pain, fatigue, fever, night sweats, and weight loss.
Pulmonary tuberculosis is diagnosed by a combination of physical examination, medical history, laboratory tests, and radiologic imaging, such as chest X-rays or computed tomography (CT) scans. Treatment for pulmonary TB usually involves a combination of antibiotics and medications to manage symptoms.
Preventive measures for pulmonary tuberculosis include screening for latent TB infection in high-risk populations, such as healthcare workers and individuals with HIV/AIDS, and vaccination with the bacillus Calmette-Guérin (BCG) vaccine in countries where it is available.
Overall, pulmonary tuberculosis is a serious and potentially life-threatening disease that requires prompt diagnosis and treatment to prevent complications and death.
There are two main types of hemolysis:
1. Intravascular hemolysis: This type occurs within the blood vessels and is caused by factors such as mechanical injury, oxidative stress, and certain infections.
2. Extravascular hemolysis: This type occurs outside the blood vessels and is caused by factors such as bone marrow disorders, splenic rupture, and certain medications.
Hemolytic anemia is a condition that occurs when there is excessive hemolysis of RBCs, leading to a decrease in the number of healthy red blood cells in the body. This can cause symptoms such as fatigue, weakness, pale skin, and shortness of breath.
Some common causes of hemolysis include:
1. Genetic disorders such as sickle cell anemia and thalassemia.
2. Autoimmune disorders such as autoimmune hemolytic anemia (AIHA).
3. Infections such as malaria, babesiosis, and toxoplasmosis.
4. Medications such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood thinners.
5. Bone marrow disorders such as aplastic anemia and myelofibrosis.
6. Splenic rupture or surgical removal of the spleen.
7. Mechanical injury to the blood vessels.
Diagnosis of hemolysis is based on a combination of physical examination, medical history, and laboratory tests such as complete blood count (CBC), blood smear examination, and direct Coombs test. Treatment depends on the underlying cause and may include supportive care, blood transfusions, and medications to suppress the immune system or prevent infection.
Bacteremia can occur when bacteria enter the bloodstream through various means, such as:
* Infected wounds or surgical sites
* Injecting drug use
* Skin infections
* Respiratory tract infections
* Urinary tract infections
* Endocarditis (infection of the heart valves)
The symptoms of bacteremia can vary depending on the type of bacteria and the severity of the infection. Some common symptoms include:
* Fever
* Chills
* Headache
* Muscle aches
* Weakness
* Confusion
* Shortness of breath
Bacteremia is diagnosed by blood cultures, which involve collecting blood samples and inserting them into a specialized container to grow the bacteria. Treatment typically involves antibiotics and supportive care, such as intravenous fluids and oxygen therapy. In severe cases, hospitalization may be necessary to monitor and treat the infection.
Prevention measures for bacteremia include:
* Practicing good hygiene, such as washing hands regularly
* Avoiding sharing personal items like toothbrushes or razors
* Properly cleaning and covering wounds
* Getting vaccinated against infections that can lead to bacteremia
* Following proper sterilization techniques during medical procedures
Overall, bacteremia is a serious condition that requires prompt medical attention to prevent complications and ensure effective treatment.
Pseudomonas infections are challenging to treat due to the bacteria's ability to develop resistance against antibiotics. The treatment typically involves a combination of antibiotics and other supportive therapies, such as oxygen therapy or mechanical ventilation, to manage symptoms and prevent complications. In some cases, surgical intervention may be necessary to remove infected tissue or repair damaged organs.
Epidemiology of Haemophilus Infections:
* Incidence: Hib disease was once a major cause of childhood meningitis and sepsis, but the introduction of Hib vaccines in the 1980s has significantly reduced the incidence of invasive Hib disease. Non-invasive Hib disease, such as otitis media, is still common.
* Prevalence: Hib is the leading cause of bacterial meningitis in children under the age of 5 worldwide. In developed countries, the prevalence of invasive Hib disease has decreased significantly since the introduction of vaccines, but it remains a significant public health problem in developing countries.
* Risk factors: young age, poverty, lack of access to healthcare, and poor sanitation and hygiene are risk factors for Hib disease. Children under the age of 5, especially those under the age of 2, are at highest risk for invasive Hib disease.
Pathophysiology of Haemophilus Infections:
* Mechanisms of infection: H. influenzae can cause both respiratory and non-respiratory infections by colonizing the nasopharynx and other mucosal surfaces. The bacteria can then disseminate to other parts of the body, causing invasive disease.
* Immune response: the immune response to Hib infection involves both humoral and cell-mediated immunity. Antibodies play a crucial role in protecting against reinfection, while T cells and macrophages help to clear the bacteria from the body.
Clinical Presentation of Haemophilus Infections:
* Respiratory infections: H. influenzae can cause various respiratory tract infections, including bronchitis, pneumonia, and sinusitis. Symptoms may include fever, cough, sore throat, and difficulty breathing.
* Non-respiratory infections: Hib can cause a range of non-respiratory infections, including meningitis, epiglottitis, and septic arthritis. These infections can have more severe symptoms and may require prompt medical attention.
Diagnosis of Haemophilus Infections:
* Diagnostic tests: diagnosis of Hib disease is based on a combination of clinical findings, laboratory tests, and radiologic studies. Blood cultures, lumbar puncture, and chest x-rays may be used to confirm the presence of the bacteria and assess the extent of infection.
* Laboratory testing: identification of Hib is based on its distinctive gram stain appearance and biochemical characteristics. Polymerase chain reaction (PCR) and DNA sequencing are also used to confirm the diagnosis.
Treatment and Prevention of Haemophilus Infections:
* Antibiotics: Hib infections are treated with antibiotics, such as amoxicillin or ceftriaxone. The choice of antibiotic depends on the severity and location of the infection.
* Vaccination: the Hib vaccine is recommended for children under 5 years old to prevent Hib disease. The vaccine is given in a series of 3-4 doses, with the first dose given at 2 months of age.
* Good hygiene practices: good hygiene practices, such as frequent handwashing and proper cleaning and disinfection, can help prevent the spread of Hib bacteria.
Complications of Haemophilus Infections:
* Meningitis: Hib meningitis can have serious complications, including hearing loss, learning disabilities, and seizures.
* Permanent brain damage: Hib infections can cause permanent brain damage, including cognitive and behavioral impairments.
* Respiratory failure: severe Hib pneumonia can lead to respiratory failure, which may require mechanical ventilation.
* Death: Hib infections can be life-threatening, especially in young children and those with underlying medical conditions.
In conclusion, Haemophilus infections are a serious public health concern, particularly for young children and those with underlying medical conditions. Prevention through vaccination and good hygiene practices is essential to reduce the risk of infection. Early diagnosis and treatment are critical to prevent complications and improve outcomes.
George Heist
Neutrophil
NOS1
Azoximer bromide
Hypochlorous acid
Timeline of immunology
Malakoplakia
List of MeSH codes (G09)
Josef von Fodor
Ernst Moro
List of MeSH codes (G04)
Galectin-4
Avarol
Neutrophil extracellular traps
Gerald Domingue
Multidrug-resistant tuberculosis
Bartonella henselae
Difloxacin
Alveolar macrophage
Prulifloxacin
Colostrum
Peptidoglycan recognition protein
Ertapenem
Primary immunodeficiency
Virucide
Hepcidin
Chronic wound
Arthropod defensin
Acetylcysteine
Brazilian purpuric fever
Aflatoxin B1
Sodium hypochlorite
Immunosenescence
Cefotaxime
Aminoglycoside
Metalloid
Meningococcal disease
Granulocyte
Leptin
Humoral immunity
Keith W. Kelley
Iron-binding proteins
Streptococcus pneumoniae
Wound licking
Mycobacterium tuberculosis
Burkholderia pseudomallei
Nitrofurantoin
Cinoxacin
Glycopeptide antibiotic
Daptomycin
Inhibition of neutrophil lysosome-phagosome fusion associated with influenza virus infection in vitro. Role in depressed...
Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the...
Clonal Distribution and Virulence of Campylobacter jejuni Isolates in Blood - Volume 19, Number 10-October 2013 - Emerging...
Recommendations for Preventing the Spread
of Vancomycin Resistance
Recommendations of the Hospital Infection Control...
Advanced Search Results - Public Health Image Library(PHIL)
Recommendations for Preventing the Spread of Vancomycin Resistance
MeSH Browser
Application of Adsorptive Blood Purification Techniques during Cardiopulmonary Bypass in Cardiac Surgery
Retinal pigment epithelial cells express antimicrobial peptide lysozyme - a novel mechanism of innate immune defense of the...
WHO EMRO | In vitro activity of gentamicin and amikacin against Salmonella enterica serovar Typhi: a search for a treatment...
Sheldon Campbell, MD, PhD | Yale School of Medicine
OPUS Würzburg | Search
MH DELETED MN ADDED MN
Cellular Components of the Immune System - Immunology; Allergic Disorders - Merck Manuals Professional Edition
DeCS
MeSH Browser
Environmental Services | Background | Environmental Guidelines | Guidelines Library | Infection Control | CDC
Research Festival | Intramural Research Program | National Institutes of Health
CEFTRIAXONE FOR INJECTION, USP
Publication Detail
Biomarkers Search
Stevia: MedlinePlus suplementos
Pesquisa | Biblioteca Virtual em Saúde - BRASIL
NIH Guide: DEEP INFECTIONS OF TOTAL JOINT REPLACEMENTS
The nature and nurture of cell heterogeneity: accounting for macrophage gene-environment interactions with single-cell RNA-Seq ...
Maternal and umbilical cord blood polymorphonuclear leukocytes showed moderate oxidative burst at phagocytosis of Gardnerella...
Serum9
- Seventy-three C. jejuni isolates from blood collected in Finland were analyzed by multilocus sequence typing and serum resistance. (cdc.gov)
- In the present study, we characterized C. jejuni blood culture isolates with respect to their clonal distribution and serum resistance. (cdc.gov)
- The same pool of serum samples from 10 healthy blood donors was used in all experiments. (cdc.gov)
- To obtain further information about the role of K-1 in serum resistance and to find out whether loss of the ability to produce K-1 can induce loss of serum resistance, we studied the serum resistance of mutants derived from completely serum-resistant, K-1-positive blood culture isolates of Escherichia coli by selection for resistance to infection with K-1 specific bacteriophages. (nih.gov)
- This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST . (nih.gov)
- Vaccines are available against all N. meningitidis serogroups except serogroup B (MenB) strains in the U.S. To identify susceptible populations, serum bactericidal assays will be utilized to investigate sero-responses based on the original Goldschneider et. (nih.gov)
- Using a study questionnaire, information on age, anthropometry, fasting blood Glucose, serum electrolytes and Cortisol were obtained and analyzed following standard procedures. (bvsalud.org)
- 16. Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. (nih.gov)
- Serum bactericidal assay (SBA) with rabbit complement and a microsphere-based flow analysis method were used to determine bactericidal titers and concentrations of IgG, respectively, against serogroups A, C, W135, and Y. Decay of antibodies was modeled using linear regression. (biomedcentral.com)
ASSAY2
- We developed and explored the feasibility of a micro titer plate-based intrinsic killing assay to screen healthy adult blood donor sera for bactericidal activity against a collection of MenB isolates. (nih.gov)
- We are currently applying this assay to screen a subset of over 400 active sera from healthy adult blood donors against diverse and epidemiologically relevant MenB strains. (nih.gov)
Virucidal activity2
- Variable killing effect Some intermediate-level disinfectants, although they are tuberculocidal, may have limited virucidal activity. (cdc.gov)
- Disinfectant - A product registered by the U.S. Environmental Protection Agency (EPA) that has demonstrated bactericidal, fungicidal and virucidal activity. (ca.gov)
Concentrations1
- Both agents showed bactericidal activity at concentrations of 2 μg/mL after incubation for 6 hours. (who.int)
Fungicidal1
- This activity is supported by the bactericidal and fungicidal properties of sulphide water. (malinowyraj.com)
Isolates4
- Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 was assessed against MnB isolates from recent disease outbreaks in France. (nih.gov)
- In a recent nationwide study over a 10-year period, we collected blood culture isolates of C. jejuni and C. coli and obtained clinical features of corresponding bacteremic episodes and characteristics of patients throughout Finland ( 10 ). (cdc.gov)
- Annual and seasonal distribution of 72 Camplyobacter jejuni blood culture isolates belonging either to the ST-677 clonal complex (CC) or to the other multilocus sequence typing (MLST) CCs. (cdc.gov)
- This study assessed the in vitro activity of gentamicin and amikacin against 464 S. enterica serovar Typhi isolates obtained from blood of patients clinically suspected of enteric fever who attended the Calcutta School of Tropical Medicine from 1991 to 2003. (who.int)
Disinfectant1
- High-level disinfectant chemicals possess sporicidal activity-only with extended exposure time are high level disinfections capable of killing high numbers of bacterial spores in laboratory tests. (cdc.gov)
Lipopolysaccharide10
- 1. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. (nih.gov)
- 3. Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis. (nih.gov)
- 5. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. (nih.gov)
- 6. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. (nih.gov)
- 8. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. (nih.gov)
- 9. Lipopolysaccharide-binding protein and bactericidal/permeability-increasing factor during hemodialysis: clinical determinants and role of different membranes. (nih.gov)
- 12. Identification and expression analysis on bactericidal permeability-increasing protein (BPI)/lipopolysaccharide-binding protein (LBP) of ark shell, Scapharca broughtonii. (nih.gov)
- 13. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. (nih.gov)
- 15. Human lipopolysaccharide-binding protein potentiates bactericidal activity of human bactericidal/permeability-increasing protein. (nih.gov)
- 17. Polymorphisms in the lipopolysaccharide-binding protein and bactericidal/permeability-increasing protein in patients with myocardial infarction. (nih.gov)
Efficacy6
- In recent ten years, with the emergence of a new adsorptive blood purification device, CytoSorb [ 6 ], hemadsorption has been gradually applied during CPB in cardiac surgery for patients at different inflammatory risks, while its efficacy, safety, and potential application need to be further discussed. (hindawi.com)
- In this study, telavancin (Vibativ ® ), a semisynthetic lipoglycopeptide antibiotic, was assessed for in vitro activity against 17 B. anthracis strains and tested for the protective efficacy against inhalation anthrax infection in the rabbit model. (listlabs.com)
- Telavancin demonstrated potent in vitro activity against B. anthracis which led us to test its efficacy in the rabbit inhalation anthrax model. (listlabs.com)
- One-step prep offers documented two-minute bactericidal efficacy. (komalhealthcare.com)
- The patented film-forming solution provides the efficacy of a five-minute scrub followed by a paint, resists wash-off by blood and saline challenge, and provides persistent activity for up to 24 hours. (komalhealthcare.com)
- In order to evaluate the bactericidal efficacy, samples were collected from the inhibitory halos and re-cultured on new bacterial culture plates. (ac.ir)
Neutrophils2
- A purified sample of neutrophils from the blood of a healthy laboratory staff volunteer collected for another unrelated study was used. (biomedcentral.com)
- 10. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. (nih.gov)
Polymorphonuclear1
- We studied the oxidative burst in polymorphonuclear leukocytes (PMNL)s from maternal blood (MB) and cord blood (CB) upon phagocytosis of GV and compared against E. coli and Group B Streptococcus (GBS). (biomedcentral.com)
Bacteria2
- Finally, surface attached bacteria are intrinsically more resistant to the action of white blood cells, and they may produce factors that impair the host response or cause direct tissue damage. (nih.gov)
- INH is the drug with the highest activity against rapidly dividing bacilli, whereas RIF and PZA have the greatest sterilizing activity against bacteria that are not dividing. (tuberculosistextbook.com)
Complement1
- al studies, where bactericidal antibodies were measured in human complement. (nih.gov)
Gram3
- Ceftriaxone contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity. (nih.gov)
- Univariate analysis indicated that preoperative Model for End-Stage Liver Disease (MELD) score >25 (P=0.005), intraoperative red blood cell infusion ≥12 U (P=0.013) and exposure to more than 2 intravenous antibiotics post-LT (P=0.003) were related to Gram-positive cocci infections. (bvsalud.org)
- Patients with high preoperative MELD score and massive intraoperative red blood cell transfusion were more likely to suffer Gram-positive cocci infection after surgery. (bvsalud.org)
Innate1
- There was also a positive correlation between infection intensity, agglutination and lysis of blood in the experimentally infested birds, which indicated activation of the constitutive innate immune system during infection. (unideb.hu)
Strains1
- Collectively, the low MICs against all strains tested and rapid bactericidal in vivo activity demonstrate that telavancin has the potential to be an effective alternative for the treatment or prophylaxis of anthrax infection. (listlabs.com)
Cells3
- Two lignin-degrading basidiomycetes, Stereum hirsutum and Heterobasidium insulare , were used to degrade bisphenol A (BPA) in culture, and the estrogenic activity of the degradation products was examined using MCF-7 cell proliferation assays (E-screen) and analysis of pS2 mRNA expression in MCF 7 cells. (go.jp)
- In comparison to control birds, infected birds showed a significantly higher concentration of white blood cells and greater blood bactericidal activity. (unideb.hu)
- The goal of this work was to investigate the synthesis of these immunologically important factors in somatic milk cells, blood cells and mammary tissue of cows with different somatic cell count levels, i.e. different immunological activity. (gene-quantification.de)
Antibacterial1
- The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. (nih.gov)
Antimicrobial1
- from the place of synthesis in hepatocytes (hep) and its antimicrobial activity (cidin). (who.int)
Sera1
- Individuals whose sera lacked bactericidal killing were at risk for developing disease. (nih.gov)
Protein2
Potent1
- The bactericidal activity of Iso amyl cyanoacrylate was found to be more potent than n-butyl + 2 octyl cyanoacrylate. (ac.ir)
Agar1
- Columbia Blood Agar with sheep blood medium (Thermo Scientific, Melaka, Malaysia) was used for subculturing of GV and GBS, and plates were incubated in 5% CO 2 at 37 °C. To prepare the bacterial suspensions, freshly streaked colonies were inoculated into Mueller Hinton Broth (MHB) (Thermo Scientific, Melaka, Malaysia), placed on a shaker and incubated at 37 °C overnight (24 h). (biomedcentral.com)
Samples4
- Peripheral blood samples were obtained after written informed consent from 10 healthy pregnant women during antenatal clinic visits or pre-delivery at the Universiti Kebangsaan Malaysia (UKM) Medical Centre, Kuala Lumpur. (biomedcentral.com)
- The eight cord blood (CB) samples were drawn from the umbilical cord arteries after delivery of the placenta. (biomedcentral.com)
- Blood samples were collected at various times post-infection to assess the level of bacteremia and antibody production, and tissues were collected to determine bacterial load. (listlabs.com)
- Blood samples for determination of leukocyte number were taken simultaneously with the biopsy samples and rectal temperature was measured at 1-h intervals. (gene-quantification.de)
Human1
- Hepcidin was first discovered in human blood hepcidin levels. (who.int)
Exposure2
- The early phase occurs when blood exposure to nonendothelial surfaces triggers a process called "contact activation," and the late phase is driven by ischemia-reperfusion (I/R) injury and endotoxemia [ 7 ]. (hindawi.com)
- We further speculate that antenatal exposure to GV may result in maternal protective immune response to the fetus, creating a difference between maternal and cord blood phagocytic responses. (biomedcentral.com)
Barrier1
- 25 mcg/mL to a value of 85% bound at 300 mcg/mL Ceftriaxone crosses the blood placenta barrier. (nih.gov)
Fetus1
- C. jejuni NCTC 11168 and a C. fetus isolate from blood were used as control organisms. (cdc.gov)
Surface1
- Contaminated - The presence of blood or other potentially infectious materials on an item-s surface or visible debris such as dust, hair and skin. (ca.gov)
Levels1
- Taking black pepper in amounts greater than those in food might cause bleeding complications or affect blood sugar levels during surgery. (webmd.com)
Successfully1
- In addition, glycosylated superoxide dismutase and catalase were successfully developed with minimal loss of enzymatic activity. (go.jp)
Black1
- Piperine, a chemical in black pepper, might slow blood clotting. (webmd.com)
Months1
- No symptoms were reported 12 months after return to sports activity. (uni-wuerzburg.de)
Coli2
- Overall, the HOCL-mediated microbicidal activity against GV is more variable and less robust than E. coli and GBS, especially in maternal than CB PMNL. (biomedcentral.com)
- Our results showed a variable and modest oxidative burst especially when PMNL from maternal blood (MB) phagocytosed GV compared to E. coli and GBS. (biomedcentral.com)
Products1
- Aged garlic products lack allicin, but may have activity due to the presence of S-allycysteine. (stuartxchange.com)
Concentration1
- Finally, the total antioxidant capacity of the blood increased significantly, while the carotenoid concentration decreased significantly in infected compared with control birds. (unideb.hu)
Healthy1
- HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS led national activity for setting priority areas. (nih.gov)
Cell1
- We also examined whether prior IV injection of ZnO ENPs altered Kupffer cell bactericidal activity on circulating Pseudomonas aeruginosa. (nih.gov)
Local1
- The local effect also involves the stimulation of microcirculation, better blood circulation and metabolism of the skin, expressed by vasomotor reaction - redness, lasting up to about 2 hours. (malinowyraj.com)
Skin1
- When allowed to dry, one-step prep delivers enhanced drape adhesion after simulated surgical conditions compared to other aqueous-based iodophor preps and provides persistent activity on skin for up to 24 hours. (komalhealthcare.com)